NL7901961A - Werkwijze voor het bereiden van een geneesmiddel voor de profylaxe en therapie van prostaathyperplasie. - Google Patents

Werkwijze voor het bereiden van een geneesmiddel voor de profylaxe en therapie van prostaathyperplasie.

Info

Publication number
NL7901961A
NL7901961A NL7901961A NL7901961A NL7901961A NL 7901961 A NL7901961 A NL 7901961A NL 7901961 A NL7901961 A NL 7901961A NL 7901961 A NL7901961 A NL 7901961A NL 7901961 A NL7901961 A NL 7901961A
Authority
NL
Netherlands
Prior art keywords
hyperplasion
prophylaxis
prostate
therapy
medicine
Prior art date
Application number
NL7901961A
Other languages
English (en)
Dutch (nl)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NL7901961A publication Critical patent/NL7901961A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NL7901961A 1978-04-17 1979-03-12 Werkwijze voor het bereiden van een geneesmiddel voor de profylaxe en therapie van prostaathyperplasie. NL7901961A (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782817157 DE2817157A1 (de) 1978-04-17 1978-04-17 Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie

Publications (1)

Publication Number Publication Date
NL7901961A true NL7901961A (nl) 1979-10-19

Family

ID=6037493

Family Applications (1)

Application Number Title Priority Date Filing Date
NL7901961A NL7901961A (nl) 1978-04-17 1979-03-12 Werkwijze voor het bereiden van een geneesmiddel voor de profylaxe en therapie van prostaathyperplasie.

Country Status (13)

Country Link
US (1) US4310523A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS5513261A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU528179B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE875634A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1134271A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (1) CH641679A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE2817157A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB2018591B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1119733B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU81153A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL7901961A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (1) SE441977B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA791797B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3121153A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie"
DE3121152A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie"
DE3339295A1 (de) * 1982-11-15 1984-05-17 Schering AG, 1000 Berlin und 4709 Bergkamen 4-hydroxy- und 4-acyloxy-4-androsten-3,17-dione zur verwendung bei der prophylaxe und therapie der prostatahyperplasie und diese enthaltende mittel fuer derartige verwendung
JPH0745382B2 (ja) * 1983-12-12 1995-05-17 カスジンスキ−，エドウイン ジ−． 毛の生長の改良
US4885289A (en) * 1983-12-12 1989-12-05 Breuer Miklos M Alteration of character of male beard growth
DE3607651A1 (de) * 1986-03-06 1987-09-10 Schering Ag Kombination von aromatasehemmer und testosteron-5(alpha)-reduktase-hemmer
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
DK0456724T3 (da) 1989-01-27 1995-10-02 Immunolytics Inc Præparat og fremgangsmåde til behandling af benign prostatisk hypertrofi
US5595985A (en) * 1989-03-10 1997-01-21 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
AU643445B2 (en) * 1989-07-07 1993-11-18 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) * 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5411991A (en) * 1992-12-22 1995-05-02 Shander; Douglas Method of reducing hair growth employing sulfhydryl active compounds
US6743419B1 (en) 1992-12-22 2004-06-01 The Gillette Company Method of reducing hair growth employing sulfhydryl active compounds
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
ATE232743T1 (de) * 1994-06-27 2003-03-15 Neutron Therapies Inc Bor enthaltende hormonanaloga und verfahren fuer ihre verwendung zur bildlichen darstellung oder zum abtoeten von zellen, die hormonrezeptoren besitzen
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
EP0833641A4 (en) * 1995-06-07 2000-04-05 Merck & Co Inc TREATMENT AND PREVENTION OF PROSTATE DISEASES
US5726202A (en) * 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
EP1321146A3 (en) * 1998-03-11 2004-06-02 Endorecherche Inc. Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use
US6541463B1 (en) 1998-03-11 2003-04-01 Endorecherche, Inc. Inhibitors of type 5 and type 3 17β-hydroxysteroid dehydrogenase and methods for their use
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
DE60021720T2 (de) 1999-05-04 2006-06-01 Strakan International Ltd. Androgen glykoside und die androgenische aktivität davon
ATE501722T1 (de) 1999-09-30 2011-04-15 Harbor Biosciences Inc Therapeutische behandlung androgenrezeptorbedingter leiden
AU2001288213B2 (en) * 2000-06-28 2005-04-14 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
AU2001271163A1 (en) * 2000-07-05 2002-01-14 Astrazeneca Ab Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
RU2188000C1 (ru) * 2001-09-27 2002-08-27 Нестерук Владимир Викторович Лекарственное средство на основе тамоксифена
US7332525B2 (en) 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
HUE037109T2 (hu) 2006-11-21 2018-08-28 Jina Pharmaceuticals Inc Endoxifén rák kezelésében történõ alkalmazásra
MX2011003726A (es) * 2008-10-10 2011-08-17 Teva Womens Health Inc Metodos para tratar sintomas vasomotores en pacientes castrados que padecen cancer prostatico con acetato de ciproterona en dosis bajas.
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3076823A (en) * 1961-07-03 1963-02-05 Syntex Corp Process for the production of 6-chloro-3-keto-deta steroid compounds
US3423507A (en) * 1966-02-25 1969-01-21 Schering Corp Method of treating benign prostratic hypertrophy
US4055641A (en) * 1976-05-10 1977-10-25 Richardson-Merrell Inc. Method of treating benign prostatic hypertrophy

Also Published As

Publication number Publication date
AU528179B2 (en) 1983-04-21
IT7921854A0 (it) 1979-04-13
SE7903240L (sv) 1979-10-18
BE875634A (fr) 1979-10-17
AU4560479A (en) 1979-10-25
US4310523A (en) 1982-01-12
JPS645007B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1989-01-27
ZA791797B (en) 1980-11-26
DE2817157A1 (de) 1979-10-25
JPS5513261A (en) 1980-01-30
IT1119733B (it) 1986-03-10
CH641679A5 (de) 1984-03-15
CA1134271A (en) 1982-10-26
GB2018591B (en) 1982-09-08
LU81153A1 (de) 1979-06-19
GB2018591A (en) 1979-10-24
SE441977B (sv) 1985-11-25

Similar Documents

Publication Publication Date Title
NL7901961A (nl) Werkwijze voor het bereiden van een geneesmiddel voor de profylaxe en therapie van prostaathyperplasie.
NL7900871A (nl) Werkwijze voor de therapeutische behandeling van hyperlipidemie en hyperlipiproteinemie.
NL7804567A (nl) Werkwijze voor het bereiden van een geneesmiddel voor het behandelen van hartklachten.
NO150760C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminotiazoler.
NO163285C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive steroider.
NL7904912A (nl) Werkwijze voor de bereiding van tertiaire alkenen.
NL185573C (nl) Werkwijze voor de bereiding van zuivere urokinase.
NL7809664A (nl) Werkwijze voor de bereiding van een huidontsmettings- zalf.
NO152414C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2,6-dialkoksybenzamider
NL7900615A (nl) Werkwijze voor de bereiding van fluorbenzonitrilen.
NL7903036A (nl) Werkwijze voor de bereiding van propeen-etheen-blok- copolymeren.
NL7900913A (nl) Werkwijze voor het verbeteren van de consistentie van een gereconstitueerde instantpuree.
NL7801564A (nl) Werkwijze voor het bereiden van (14-14c)- -daunorubicine en (14-14c)-doxorubicine.
NL7601550A (nl) Werkwijze voor de bereiding van therapeutische composties voor het genezen van tandcaries.
NL7811106A (nl) Werkwijze voor de bereiding van moranoline en n-methylmoranoline.
NL7903251A (nl) Werkwijze voor de bereiding van cefalosporinen.
NL176674B (nl) Werkwijze ter bereiding van een geneesmiddel voor de behandeling van circulatiestoringen en werkwijze ter bereiding van de geneeskrachtige verbindingen.
NL188524B (nl) Werkwijze voor de bereiding van p-aminofenol.
JPS54141797A (en) Therapeutic drug
NL7600047A (nl) Werkwijze voor het bereiden van farmaceutische preparaten voor het behandelen van storingen van de bloedsomloop.
NL7704085A (nl) Werkwijze voor het bereiden van bis-peni- cillanoyloxyalkenen met geneeskundige activi- teit.
NL7901407A (nl) Werkwijze voor de bereiding van pyrethrinen en analoga daarvan.
NL189650C (nl) Farmaceutische preparaten voor het behandelen van wonden.
NL7902958A (nl) Werkwijze voor het bereiden van tetrahydroalstonine- derivaten en de toepassing hiervan als therapeutisch middel.
ZA7626B (en) Pharmaceutical preparations for the treatment of coronary heart diseases

Legal Events

Date Code Title Description
A85 Still pending on 85-01-01
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BC A request for examination has been filed
BV The patent application has lapsed